Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $544,327.25 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider Jonathan Gillis sold 17,935 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $30.35, for a total transaction of $544,327.25. Following the completion of the sale, the insider directly owned 181,219 shares in the company, valued at approximately $5,499,996.65. The trade was a 9.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Gillis also recently made the following trade(s):

• On Monday, April 27th, Jonathan Gillis sold 51,900 shares of Maplight Therapeutics stock. The shares were sold at an average price of $29.74, for a total transaction of $1,543,506.00.

Maplight Therapeutics Trading Down 3.7%

Shares of NASDAQ:MPLT opened at $30.70 on Friday. The company’s fifty day moving average is $22.19. The firm has a market cap of $1.30 billion and a PE ratio of -0.77. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last announced its earnings results on Thursday, March 26th. The company reported ($2.47) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). As a group, equities analysts anticipate that Maplight Therapeutics, Inc. will post -3.87 EPS for the current year.

Institutional Investors Weigh In On Maplight Therapeutics

Several hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Maplight Therapeutics during the fourth quarter worth $49,168,000. Invesco Ltd. acquired a new stake in shares of Maplight Therapeutics during the fourth quarter worth $228,000. Vestal Point Capital LP acquired a new stake in shares of Maplight Therapeutics in the fourth quarter worth approximately $6,763,000. Tudor Investment Corp ET AL acquired a new stake in shares of Maplight Therapeutics in the fourth quarter worth approximately $840,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of Maplight Therapeutics in the fourth quarter worth approximately $952,000.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on MPLT shares. Weiss Ratings started coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Needham & Company LLC began coverage on shares of Maplight Therapeutics in a report on Wednesday, April 8th. They set a “buy” rating and a $37.00 price target for the company. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They set a “buy” rating and a $35.00 price target for the company. Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, TD Cowen began coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They set a “buy” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.67.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.